NovaBay's impetigo drug aces Phase II trial

NovaBay Pharmaceuticals' lead drug candidate NVC-422 was shown to be safe and effective in a mid-stage trial. The drug was tested at three doses against the contagious skin infection impetigo, including infections caused bymethicillin-resistant Staphylococcus aureus (MRSA). Results showed a trend towards a dose response. NovaBay says in a statement that it plans to "aggressively" pursue development of NVC-422 as a first-line treatment for a range of topical infections. Release